Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection

Human Gene Therapy

Volumn 13, Issue 12, 2002, Pages 1415-1425

  Kumar, Mukesh ^a   Behera, Aruna K ^a   Lockey, Richard F ^a   Zhang, Jian ^a   Bhullar, Guraman ^a   Perez de la Cruz, Cristina ^b   Chen, Li Chen ^c   Leong, Kam W ^b   Huang, Shau Ku ^c   Mohapatra, Shyam S ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MESSENGER RNA; METHACHOLINE; MICROSPHERE; PLASMID DNA; PROTEIN; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; BRONCHUS REACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE TRANSFER; GENETIC CODE; HUMAN; HUMAN CELL; INFECTION PREVENTION; LUNG INFECTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SPLEEN CELL; VIRUS INFECTION; VIRUS LOAD; VIRUS TITRATION;

ANIMALS; ANTIGENS, VIRAL; BIOPOLYMERS; CHITIN; CHITOSAN; DRUG CARRIERS; FEMALE; GENE THERAPY; GENETIC VECTORS; INTERFERON TYPE II; LUNG; MICE; MICE, INBRED BALB C; PLASMIDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL LOAD; VIRAL VACCINES;

ANIMALIA; BRONCHUS; PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; RNA VIRUSES;

EID: 0036382826     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340260185058     Document Type: Article

References (40)

1. ABERLE, J.H., ABERLE, S.W., ALLISON, S.L., STIASNY, K., ECKER, M., MANDL, C.W., BERGER, R., and HEINZ, F.X. (1999). A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms. J. Immunol. 163, 6756-6761.
2. ARTURSSON, P., LINDMARK, T., DAVIS, S.S., and ILLUM, L. (1994). Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11, 1358-1361.
3. BEHERA, A.K., KUMAR, M., MATSUSE, H., LOCKEY, R.F., and MOHAPATRA, S.S. (1998). Respiratory syncytial virus induces the expression of 5-lipoxygenase and endothelin-1 in bronchial epithelial cells. Biochem. Biophys. Res. Commun. 251, 704-709.
4. BEHERA, A.K., MATSUSE, H., KUMAR, M., KONG, X., LOCKEY, R.F., and MOHAPATRA, S.S. (2001). Blocking intercellular adhesion molecule-I on human epithelial cells decreases respiratory syncytial virus infection. Biochem. Biophys. Res. Commun. 280, 188-195.
5. BIANCO, I.D., BALSINDE, J., BELTRAMO, D.M., CASTAGNA, L.F., LANDA, C.A., and DENNIS, E.A. (2000). Chitosan-induced phospholipase A2 activation and arachidonic acid mobilization in P388D1 macrophages. FEBS Lett. 466, 292-294.
6. BOMSEL, M., HEYMAN, M., HOCINI, H., LAGAYE, S., BELEC, L., DUPONT, C., and DESGRANGES, C. (1998). Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9, 277-287.
7. BRANDENBURG, A.H., NEIJENS, H.J., and OSTERHAUS, A.D. (2001). Pathogenesis of RSV lower respiratory tract infection: Implications for vaccine development. Vaccine 19, 2769-2782.
8. CANNON, M.J., STOTT, E.J., TAYLOR, G., and ASKONAS, B.A. (1987). Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology 62, 133-138.
9. CENTERS FOR DISEASE CONTROL AND PREVENTION (1999). Update: Respiratory syncytial virus activity-United States, 1998-1999 season. MMWR 48, 1104.
10. CHANOCK, R.M., PARROTT, R.H., CONNORS, M., COLLINS, P.L., and MURPHY, B.R. (1992). Serious respiratory tract disease caused by respiratory syncytial virus: Prospects for improved therapy and immunization. Pediatrics 90, 137-143.
11. COHEN, A.D., BOYER, J.D., and WEINER, D.B. (1998). Modulating the immune response to genetic immunization. FASEB J. 12, 1611-1626.
12. CONNORS, M., COLLINS, P.L., FIRESTONE, C.Y., and MURPHY, B.R. (1991). Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65, 1634-1637.
13. DOMACHOWSKE, J.B., and BONVILLE, C.A. (1998). Overnight titration of human respiratory syncytial virus using quantitative shell vial amplification. Biotechniques 25, 644-647.
14. DOMACHOWSKE, J.B., and ROSENBERG, H.F. (1999). Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment. Clin. Microbiol. Rev. 12, 298-309.
15. DONNELLY, J.J., ULMER, J.B., and LIU, M.A. (1998). DNA vaccines. Dev. Biol. Stand. 95, 43-53.
16. FERNIE, B.F., FORD, E.C., and GERIN, J.L. (1981). The development of BALB/c cells persistently infected with respiratory syncytial virus: Presence of ribonucleoprotein on the cell surface. Proc. Soc. Exp. Biol. Med. 167, 83-86.
17. GODDING, V., VAERMAN, J.P., and SIBILLE, Y. (2000). Secretory mucosal immune mechanisms. Acta Otorhinolaryngol. Belg. 54, 255-261.
18. GRAHAM, B.S., BUNTON, L.A., WRIGHT, P.F., and KARZON, D.T. (1991). Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 88, 1026-1033.
19. GROOTHUIS, J.R., LEVIN, M.J., RODRIGUEZ, W., HALL, C.B., LONG, C.E., KIM, H.W., LAUER, B.A., and HEMMING, V.G. (1991). Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: Safety and pharmacokinetics. RSVIG Study Group. Antimicrob. Agents Chemother. 35, 1469-1473.
20. GUY, B., PASCAL, N., FRANCON, A., BONNIN, A., GIMENEZ, S., LAFAY-VIALON, E., TRANNOY, E., and HAENSLER, J. (2001). Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19, 1794-1805.
21. HALL, C.B. (1994). Prospects for a respiratory syncytial virus vaccine. Science 265, 1393-1394.
22. HEMMING, V.G., PRINCE, G.A., GROOTHUIS, J.R., and SIBER, G.R. (1995). Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8, 22-33.
23. HSU, S.C., OBEID, O.E., COLLINS, M., IQBAL, M., CHARGELEGUE, D., and STEWARD, M.W. (1998). Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: Involvement of IFN-γ. Int. Immunol. 10, 1441-1447.
24. ILLUM, L., JABBAL-GILL, I., HINCHCLIFFE, M., FISHER, A.N., and DAVIS, S.S. (2001). Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51, 81-96.
25. KNEYBER, M.C., MOLL, H.A., and DE GROOT, R. (2000). Treatment and prevention of respiratory syncytial virus infection. Eur. J. Pediatr. 159, 399-411.
26. KUMAR, M., BEHERA, A.K., MATSUSE, H., LOCKEY, R.F., and MOHAPATRA, S.S. (1999). Intranasal IFN-γ gene transfer protects BALB/c mice against respiratory syncytial virus infection. Vaccine 18, 558-567.
27. LI, X., SAMBHARA, S., LI, C.X., EWASYSHYN, M., PARRINGTON, M., CATERINI, J., JAMES, O., CATES, G., DU, R.P., and KLEIN, M. (1998). Protection against respiratory syncytial virus infection by DNA immunization. J. Exp. Med. 188, 681-688.
28. LI, X., SAMBHARA, S., LI, C.X., ETTORRE, L., SWITZER, I., CATES, G., JAMES, O., PARRINGTON, M., OOMEN, R., DU, R.P., and KLEIN, M. (2000). Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 269, 54-65.
29. MATSUO, K., MACLAUGHLIN, F.C., MUMPER, R.J., WANG, J., TAGLIAFERRI, J.M., GILL, I., HINCHCLIFFE, M., and ROLLAND, A.P. (2000). Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). Vaccine 18, 2713-2722.
30. MATSUSE, H., BEHERA, A.K., KUMAR, M., RABB, H., LOCKEY, R.F., and MOHAPATRA, S.S. (2000). Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness. J. Immunol. 164, 6583-6592.
31. MAZANEC, M.B., KAETZEL, C.S., LAMM, M.E., FLETCHER, D., and NEDRUD, J.G. (1992). Intracellular neutralization of virus by immunoglobulin A anti-bodies. Proc. Natl. Acad. Sci. U.S.A. 89, 6901-6905.
32. NICHOLAS, J.A., RUBINO, K.L., LEVELY, M.E., ADAMS, E.G., and COLLINS, P.L. (1990). Cytolytic T-lymphocyte responses to respiratory syncytial virus: Effector cell phenotype and target proteins. J. Virol. 64, 4232-4241.
33. NISHIMURA, K., NISHIMURA, S., NISHI, N., SAIKI, I., TOKURA, S., and AZUMA, I. (1984). Immunological activity of chitin and its derivatives. Vaccine 2, 93-99.
34. + effector T cells is differentially regulated by IL-18 and IL-12. J. Immunol. 162, 3202-3211.
35. OTTERLEI, M., VARUM, K.M., RYAN, L., and ESPEVIK, T. (1994). Characterization of binding and TNF-α inducing ability of chitosans on monocytes: The involvement of CD14. Vaccine 12, 825-832.
36. PRINCE, G.A., CAPIAU, C., DESCHAMPS, M., FABRY, L., GARCON, N., GHEYSEN, D., PRIEELS, J.P., THIRY, G., VAN OPSTAL, O., and PORTER, D.D. (2000). Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycopro-tein vaccine in cotton rats. J. Virol. 74, 10287-10292.
37. RICHARDSON, S.C., KOLBE, H.V., and DUNCAN, R. (1999). Potential of low molecular mass chitosan as a DNA delivery system: Biocompatibility, body distribution and ability to complex and protect DNA. Int. J. Pharm. 178, 231-243.
38. ROY, K., MAO, H.Q., HUANG, S.K., and LEONG, K.W. (1999). Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5, 387-391.
39. SEO, W.G., PAE, H.O., KIM, N.Y., OH, G.S., PARK, I.S., KIM, Y.H., KIM, Y.M., LEE, Y.H., JUN, C.D., and CHUNG, H.T. (2000). Synergistic cooperation between water-soluble chitosan oligomers and interferon-γ for induction of nitric oxide synthesis and tumoricidal activity in murine peritoneal macrophages. Cancer Lett. 159, 189-195.
40. WYATT, L.S., WHITEHEAD, S.S., VENANZI, K.A., MURPHY, B.R., and MOSS, B. (1999). Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18, 392-397.